E-cadherin expression in upper-urinary-tract carcinoma

Abstract

Carcinoma of the upper urinary tract is a relatively rare neoplasm, and few studies have dealt with clinicopathological findings and prognosis in a large number of cases. The purpose of our investigation was to look for a possible relation between E-cadherin (E-CD) immunoreactivity and clinico-pathologic findings or clinical outcome in transitional-cell carcinoma of the upper urinary tract (TCC-UUT). To this end, we investigated E-CD immunoreactivity in 154 cases of TCC-UUT. E-CD immunoreactivity was recognized as being of ''normal'' pattern in 29.2% of samples. The relationship between E-CD immunoreactivity and clinicopathologic findings was significant for stage, grade and pattern of growth. The 5-year disease-free rate for 147 cases and 5-year overall survival rate for 154 cases were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth and E-CD immunoreactivity all had a significant effect on disease-free and overall survival rates. In the final models of multivariate analysis, however, we found that, for disease-free survival and for overall survival, only stage was a factor for progression or prognosis. Detection of E-CD immunoreactivity appears to be of limited value in deciding the prognosis of TCC-UUT. Int.

Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract

“…The clinicopathological features of these same patients have been reported elsewhere [24]. Briefly, the patients' age at diagnosis was in the range 34 to 84 years, with a median age of 66 years.…”

“…Another study in these same patients has been reported elsewhere [23,24]. Histopathological stage was determined according to the criteria proposed by the International Union Against Cancer (UICC) [29].…”

Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract

“…Although prognostic significance has been established for both stage and grade [4,6], it is important to identify prognostic markers that will predict which patients are likely to experience disease progression. Several markers, including epithelial growth factor receptor, p53, E-cadherin, and HIF-1α, are known to be associated with progression and prognosis in TCC-UUT [18][19][20][21][22]. The purpose of our investigation was to look for possible relations between LAT1 (protein and mRNA) expression and PCNA index, clinicopathologic findings, or clinical outcome in TCC-UUT.…”

The Prognostic Importance of E-cadherin and p53 Gene Expression in Transitional Bladder Carcinoma Patients

“…E-cadherin is the primary mediator of calciumdependent cell-cell adhesion in epithelial tissues [16,19]. Loss of functional e-cadherin expression has been implicated in carcinogenesis as it is frequently observed in human epithelial cancers, including bladder cancer [13][14][15][20][21][22][23][24][25]. Furthermore, loss of e-cadherin-mediated cell adhesion coincides with the transition from well-differentiated adenoma to invasive carcinoma, supporting its role as a rate-limiting step in the progression to invasive disease [26].…”